ArticleBMC endocrine disorders2026
Utility of albumin-adjusted calcium and calcium‒phosphorus difference in screening for primary hyperparathyroidism.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary hyperparathyroidism (PHPT) is often asymptomatic but increases the risk of osteoporosis, fractures, and cardiovascular mortality. We evaluated the effectiveness of albumin-adjusted calcium (aCa) formulas and the calcium–phosphorus (Ca–P) difference as prescreening tools for PHPT in health checkup populations.
methodsWe analyzed 5550 corresponding measurements of total calcium (tCa), serum albumin (Alb), and ionized calcium (iCa) to evaluate the consistency between iCa and tCa and between iCa and three aCa formulas (Payne, KDOQI-2, and James). Receiver operating characteristic (ROC) curve analyses were performed for 64 PHPT patients and 87 controls. Cutoffs were then applied to 2562 health checkup participants.
resultsThe James formula demonstrated the strongest agreement with iCa (κ = 0.60), outperforming the tCa and other formulas. ROC curve analyses revealed that the James-based Ca–P difference (AUC = 0.965) surpassed all other calcium-based indices and approached the intact parathyroid hormone value (AUC = 0.983), with respective sensitivities and specificities of 0.88 and 0.94. In the health checkup cohort, the PHPT prevalence was 0.17%. Identifying all four confirmed cases required investigating 64 candidates of tCa, nine to ten of aCa, and only five to seven of the Ca–P difference.
conclusionsDetermining the albumin-adjusted calcium, particularly by the James formula, improved PHPT prescreening compared with tCa alone. The Ca–P difference demonstrated even better diagnostic performance. In populations where fasting phosphorus is routinely measured, the Ca–P difference reduces the number of candidates requiring confirmatory testing, providing a potentially resource-efficient strategy for early PHPT detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.